In this issue:
New European guidelines for the treatment of MS
Risk of natalizumab-associated PML
Clinically silent T2 lesions affect cognition in early MS
Comorbidities increase the risk of relapse
Alemtuzumab: CARE-MS II 5-year follow-up
Epilepsy in MS
Dimethyl fumarate: an exit strategy from natalizumab treatment?
Gait patterns when texting while walking
Severe MS reactivation after fingolimod cessation
Osteopontin as a biomarker for MS
Please login below to download this issue (PDF)